Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 11/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | PDE5A | O76074 | 1/20 | 0.54 |
| ▸ | TNKS | O95271 | 6/20 | 0.52 |
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.52 |
| ▸ | PARP1 | P09874 | 4/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14845878 | 0.87 | GUSB (0.63) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL1084872 | 0.83 | GUSB (0.78) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL29740691 | 0.83 | GUSB (0.78) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL17254827 | 0.81 | GUSB (0.49) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL13604403 | 0.81 | GUSB (0.69) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL7160589 | 0.80 | GUSB (1.00) | GUSBKDM4EHPGDPDE5A | |
| SCHEMBL31238756 | 0.80 | GUSB (1.00) | GUSBKDM4EHPGDPDE5A | |
| SCHEMBL10205334 | 0.80 | GUSB (0.68) | GUSBKDM4EHPGDPDE5ATNKS | |
| SCHEMBL4579539 | 0.80 | GUSB (0.67) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL28146251 | 0.80 | GUSB (0.65) | GUSBKDM4EHPGDTNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2366696-A1 | Process for producing 4-aminoquinazolines | Vertex Pharmaceuticals Incorporated (US) | 2011-09-21 | — | — | EP | claimed |
| EP-1828150-A2 | PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES | Vertex Pharmaceuticals Incorporated (US) | 2007-09-05 | — | — | EP | claimed |
| US-20060166963-A1 | Processes for producing 4-aminoquinazolines | VERTEX PHARMACEUTICALS INCORPORATED | 2006-07-27 | — | — | US | claimed |
| WO-2006066044-A2 | PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-22 | — | — | WO | claimed |
| EP-1828150-B1 | PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES | VERTEX PHARMA (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2366696-A1 | Process for producing 4-aminoquinazolines | Vertex Pharmaceuticals Incorporated (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-1828150-A2 | PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES | Vertex Pharmaceuticals Incorporated (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060166963-A1 | Processes for producing 4-aminoquinazolines | VERTEX PHARMACEUTICALS INCORPORATED | 2006-07-27 | — | — | US | disclosed |
| WO-2006066044-A2 | PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-22 | — | — | WO | disclosed |
| EP-0641351-B1 | ENZYMATIC ANALYSIS USING SUBSTRATES THAT YIELD FLUORESCENT PRECIPITATES | MOLECULAR PROBES INC (US) | 1996-10-23 | — | — | EP | disclosed |
| US-5443986-A | Enzymatic analysis using substrates that yield fluorescent precipitates | MOLECULAR PROBES, INC. (US) | 1995-08-22 | — | — | US | disclosed |
| US-5316906-A | Fluorescent dyes for substrates | MOLECULAR PROBES, INC. (US) | 1994-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166963-A1 | Processes for producing 4-aminoquinazolines | CACNA1I, CACNA1G, CACNA1B | GUSB 4518/4885KDM4E 1377/4885HPGD 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.